Tacrolimus capsules, manufactured by Panacea Biotec Limited, are an immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, or heart transplants. The medication is used in combination with other immunosuppressants.
Mechanism of Action and Pharmacokinetics
Tacrolimus inhibits calcineurin, preventing the dephosphorylation and translocation of factors like NF-AT and NF-κB, thereby suppressing cytokine expression including IL-1 beta, IL-2, and TNF-alpha. This results in the inhibition of T-lymphocyte activation and proliferation. Pharmacokinetic data indicates that whole blood concentrations are more appropriate than plasma concentrations for describing tacrolimus activity.
Common Adverse Reactions and Dosage
In kidney transplant trials (N=412), the most common adverse reactions (≥30%) included infection, tremor, hypertension, abnormal renal function, constipation, diarrhea, headache, abdominal pain, insomnia, nausea, hypomagnesemia, urinary tract infection, hypophosphatemia, peripheral edema, asthenia, pain, hyperlipidemia, hyperkalemia, and anemia. Nephrotoxicity was reported in approximately 52% of kidney transplant patients. Dosage adjustments are recommended for African-American patients, and those with hepatic or renal impairment. Initial oral dosages range from 0.2 mg/kg/day to 0.3 mg/kg/day, divided into two doses every 12 hours, depending on the organ transplant type. Therapeutic drug monitoring is recommended. Patients should avoid grapefruit consumption. The medication’s effectiveness is dependent on consistent administration.